April 05, 2017
Datamonitor Healthcare interviewed two inflammatory bowel disease experts, one based in France and the other in Italy, to gauge their views on marketed drugs for Crohn’s disease (CD), late-stage clinical candidates, treatment challenges and unmet needs and the future treatment of CD. The drugs discussed are listed below. The two interviews were combined into a single report.
Azasan (VRX), Cimzia, Cx601 (TIG), Entocort EC (PRGO), Entyvio (TKPYY), etrolizumab (RHHBF), filgotinib (GILD), GED 0301 (CELG), Humira (ABBV), Remicade (JNJ), Stelara (JNJ), Tysabri (BIIB), Xeljanz/Xeljanz XR (PFE).
Crohn’s Disease – sample page 3

Crohn’s Disease – sample page 4
